Reprint
Frontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis
Edited by
January 2023
318 pages
- ISBN978-3-0365-6121-9 (Hardback)
- ISBN978-3-0365-6122-6 (PDF)
This book is a reprint of the Special Issue Frontiers of Targeted Therapy and Predictors of Treatment Response in Systemic Sclerosis that was published in
Biology & Life Sciences
Medicine & Pharmacology
Summary
Systemic sclerosis (scleroderma) is an incurable connective tissue disease with an unclear etiology characterized by vasculopathy, dysregulation of the immune response, and progressive tissue fibrosis affecting the skin, lungs, digestive tract, heart, and kidneys. The collection of six original research manuscripts and five review articles included in this book highlights the most recent advances in this field and provides further elucidation of the pathogenesis, natural disease course, and treatment of this challenging disease.
Format
- Hardback
License
© 2022 by the authors; CC BY-NC-ND license
Keywords
heat shock protein 90; systemic sclerosis; established dermal fibrosis; treatment; systemic sclerosis; pathogenesis; epigenetic mechanisms; miRNAs; calcinosis cutis; bisphosphonates; pamidronate; autoimmune connective tissue diseases; systemic sclerosis; dermatomyositis; treatment; systemic sclerosis; immune cells; anti-inflammatory; therapy; fibrosis; systemic sclerosis; interleukin-6; Tocilizumab; pulmonary fibrosis; systemic sclerosis; interstitial lung disease; progressive fibrosing interstitial lung disease; lung function; body mass index; treatment; systemic sclerosis; interstitial lung disease; clinical trial; systemic sclerosis; metabolomics; LC-MS/MS; ion mobility; kynurenine pathway; urea cycle; lipids; gut dysbiosis; systemic sclerosis; pulmonary arterial hypertension (PAH); biomarkers; miRNA; complement; myofibroblasts; macitentan; systemic sclerosis; interstitial lung disease; cough; pulmonary hypertension; predictors of treatment response; systemic sclerosis; autoreactive B cells; autoantibodies; rituximab; aptamers; Seldeg; n/a; interstitial lung disease; systemic sclerosis; mixed connective tissue disease; systemic lupus erythematosus; Sjögren’s syndrome; rheumatoid arthritis; idiopathic inflammatory myopathy; national delphi consensus